Modelling HDV kinetics under the entry inhibitor bulevirtide suggests the existence of two HDV-infected cell populations

• Published in: JHEP reports Vol. 6; no. 2; p. 100966
• Main Authors: Shekhtman, Louis, Cotler, Scott J., Degasperi, Elisabetta, Anolli, Maria Paola, Uceda Renteria, Sara Colonia, Sambarino, Dana, Borghi, Marta, Perbellini, Riccardo, Facchetti, Floriana, Ceriotti, Ferruccio, Lampertico, Pietro, Dahari, Harel
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.02.2024; Elsevier
• Subjects: ALT; Bulevirtide; Gastroenterology and Hepatology; HBsAg; HDV RNA; mathematical modeling; LLoQ; BF; HBsAg; ALT; FPR; HDV RNA; TND; Bulevirtide; BLV; CSPH; mathematical modeling; HDV; HBV; CHD; hepatitis B surface antigen; chronic hepatitis D; hepatitis B virus; alanine aminotransferase; flat-partial response; body fluid; clinically significant portal hypertension; target not detected; hepatitis D virus; lower limit of quantification

Bulevirtide (BLV) was approved for the treatment of compensated chronic hepatitis D virus (HDV) infection in Europe in 2020. However, research into the effects of the entry inhibitor BLV on HDV-host dynamics is in its infancy. Eighteen patients with HDV under nucleos(t)ide analogue treatment for hep...